Navigation Links
Argonne-SRNL agreement supports critical DOE, national priorities
Date:5/15/2008

Argonne, Ill. (May 15, 2008) Argonne National Laboratory has signed a memorandum of understanding (MOU) with Savannah River National Laboratory (SRNL) to collaborate on nuclear energy and environmental management research projects in support of critical U.S. Energy Department (DOE) needs and other important national priorities.

"The MOU allows Argonne to remain a leader in nuclear energy research," Argonne director Robert Rosner said. "Argonne has the nation's largest concentration of scientists and engineers involved in fast-reactor design and nuclear fuel separations and processing technologies expertise that is essential to developing next-generation nuclear energy systems, a key component of President Bush's Global Nuclear Energy Partnership" (GNEP), Rosner added.

The agreement will bring together the strengths of the two National Laboratories, including SRNLs applied science and engineering expertise and their nuclear facilities for the safe handling and study of highly radioactive materials. The SRNL facilities include the Shielded Cells, where highly skilled employees use remote manipulator arms to perform work with radioactive samples, while safely protected behind thick shielding. Argonne brings to the partnership scientific and engineering expertise and state-of-the-art radiological facilities for studying chemical phenomena at the smallest scale. Among the facilities that may be used in understanding materials properties include the Advanced Photon Source, the brightest x-ray beam in the western hemisphere.

This agreement blends the key skills and capabilities from SRNL and Argonne for advancing U.S. nuclear energy capabilities. SRNLs core competencies for the development and deployment of applied technology solutions for safe nuclear facilities operation will help this partnership make advances that support important energy independence initiatives for the nation, said Dr. G. Todd Wright, SRNL Laboratory Director.

Argonne and SRNL will collaborate in areas in which the two research facilities have complementary strengths, including actinide chemistry, separations science and technology, and computational chemistry and modeling. "Advances in these research areas are vital for any U.S. expansion of the use of safe, clean nuclear energy, closing the nuclear fuel cycle, and management of legacy nuclear materials," said Mark Peters, Argonne's program manager for GNEP and the Deputy to the Associate Laboratory Director of Energy Sciences and Engineering.

Actinide chemistry involves the study of radioactive heavy metals, such as uranium, neptunium, and plutonium, that are indigenous to nuclear energy processes. Maintenance of a core competency associated with actinide science is critical in order to sustain continued growth of nuclear programs in the U.S. and to effectively treat legacy nuclear materials. Argonnes actinide experience dates back to the earliest days of the Manhattan Project and is focused on basic scientific understanding and knowledge. SRNLs experience, which dates back to the early 1950s, has been generally focused on production-scale deployment, including the design and development of specialized technologies for the safe characterization, purification, stabilization, and disposition of these materials.

Separations science involves the design, study, and application of processes for separating mixtures of compounds into their component substances. The two laboratories have made significant contributions to the field over their histories. These contributions date to the earliest years of the U.S. nuclear enterprise and continue to support such national initiatives as GNEP. The labs will develop a joint plan for advancing separations science and technology programs to meet the current and future needs of DOE with a focus on the DOE Offices of Nuclear Energy (DOE-NE) and Environmental Management (DOE-EM).


'/>"/>

Contact: Angela Hardin
ahardin@anl.gov
630-252-5501
DOE/Argonne National Laboratory
Source:Eurekalert

Related biology news :

1. Great Ape Trust signs agreement with Universitas Nasional in Jakarta
2. U. Mass Medical School and Carnegie announce licensing agreements with Oxford BioMedica
3. Lockheed Martin Advances Biometrics Portfolio Through Cooperation Agreement With Cognitec
4. SAGE and Hindawi announce landmark open access agreement
5. USDA Cooperative Agreement funds mosquito project at Rutgers
6. More on mate tea: lower cholesterol and an international agreement
7. Saflink and IdentiPHI Announce Merger Agreement
8. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
9. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
10. Saflink and IdentiPHI Announce Merger Agreement
11. American Society for Microbiology supports One Health initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:2/28/2017)... , Feb. 28, 2017   Acuant , ... software globally, announces significant enhancements to new and core ... 2016. New products include mobile and desktop Acuant FRM ... TM - a real time manual review of ... idScan® technology provides the fastest and most accurate capture ...
(Date:2/26/2017)... DALLAS , Feb. 25, 2017  Securus ... justice technology solutions for public safety, investigation, corrections ... of Recidivism and Reentry. "Too often, ... State prisons and county jails are trying to ... of inmates and friends and family members. While significant ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused on ... today that Dr. Miriam Kidron , Oramed,s ... "Oral Insulin for Diabetes Treatment: Bypassing the Roadblock," ... Peptide Therapeutics (OPT) Boston Conference in Cambridge, ...
(Date:3/22/2017)... /PRNewswire/ - FACIT announced a seed stage investment ... start-up created by FACIT focused on developing a ... with non-dilutive capital, achieves a targeted $3.0M financing ... Propellon to accelerate the nomination of a candidate ... entering a strategic partnership for clinical trials in ...
(Date:3/22/2017)... ... , ... Okyanos Cell Therapy has announced Tallahassee, FL will be the next ... Cell Therapy: The Next Phase in the Evolution of Medicine.” As the Bahamas’ first ... Therapy Act, Okyanos maintains a mission to help “no-option” patients and those with ...
(Date:3/22/2017)... ... March 21, 2017 , ... The Conference Forum has announced the launch ... held on May 10-11, 2017, at the Colonnade Hotel in Boston, MA. The CMO ... Officer peer-to-peer learning, benchmarking and support. , “The Chief Medical Officer faces a unique ...
Breaking Biology Technology: